ArticleBMC cancer2021

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

Ho Wai Derrick Siu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.